Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Leukemia and Lymphoma

• Publication date

  1996-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/10428199609074368PMID 8951781
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Informed consent in European multicentre randomised clinical trials--are patients really informed?

  1994cited by this paper
• Quality of life assessment in clinical cancer research.

  1994cited by this paper
• Problems in clinical trials go far beyond misconduct.

  1994cited by this paper
• The very‐long‐term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group

  1994cited by this paper
• Is informed consent essential for all chemotherapy studies?

  1994cited by this paper
• Centralised treatment, entry to trials and survival.

  1994cited by this paper
• Long‐range effect of clinical trial interventions on quality of life

  1994cited by this paper
• Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity with therapeutic implications

  1994cited by this paper
• Randomized clinical trials in oncology: Principles and obstacles

  1994cited by this paper
• Secondary malignancies after bone marrow transplantation in adults.

  1994cited by this paper
• Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party.

  1993cited by this paper
• Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group.

  1993cited by this paper
• Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea.

  1993cited by this paper
• Users' guides to the medical literature.

  1993cited by this paper
• Estimates of the worldwide incidence of eighteen major cancers in 1985

  1993cited by this paper
• Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden

  1993cited by this paper
• [Treatment of polycythemia with 32P with or without hydroxyurea maintenance therapy. Preliminary results in 237 elderly and high vascular risk subjects studied since 1980].

  1993cited by this paper
• Radiotherapy- and chemotherapy-induced myelodysplasia and acute myeloid leukemia. A review.

  1992cited by this paper
• [Treatment of polycythemia vera with hydroxyurea or pipobroman. Efficacy and toxicity analysed from a protocol of 96 patients under 65 years of age. Le Groupe d'Etude des Polyglobulies].

  1992cited by this paper
• Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study.

  1991cited by this paper
• Leukemic transformation in polycythemia vera: Analysis of risk factors

  1990cited by this paper
• Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea *

  1988cited by this paper
• Acute leukemia and myelodysplasia in polycythemia vera. A clinical study with long‐term follow‐up

  1988cited by this paper
• Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years

  1987cited by this paper
• Acute leukemia in polycythemia vera.

  1986cited by this paper
• Treatment of polycythemia vera with hydroxyurea

  1986cited by this paper
• Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia.

  1984cited by this paper
• The ‘spent’phase of polycythaemia vera: hypersplenism in the absence of myelofibrosis

  1984cited by this paper
• Cytogenetic studies on acute nonlymphocytic leukemias following polycythemia vera.

  1984cited by this paper
• Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

  1977cited by this paper
• Acute leukemia in polycythemia vera.

  1976cited by this paper
• Postpolycythemia myeloid metaplasia.

  1974cited by this paper
• Leukemia in polycythemia vera. Relationship to splenic myeloid metaplasia and therapeutic radiation dose.

  1969cited by this paper
• A study of hematological complications occurring in patients with polycythemia vera treated with 32-P (based on a series of 296 patients).

  1968cited by this paper
• Polycythemia vera complicated by acute leukemia and a rapidly enlarging mass in the left upper abdominal quadrant.

  1967cited by this paper
• Radiation-related leukemia in Hiroshima and Nagasaki, 1946-1964. I. Distribution, incidence and appearance time.

  1966cited by this paper
• POLYCYTHEMIA VERA AND LEUKEMIA—THE ROLE OF RADIATION TREATMENT: A STUDY OF 1222 PATIENTS

  1965cited by this paper
• POLYCYTHEMIA VERA: AGE RELATIONSHIPS AND SURVIVAL.

  1965cited by this paper

• The Development of Primary Effusion Lymphoma-Like Lymphoma in a Patient with Preexisting Essential Thrombocythemia

  2021cites this paper
• Risks of Solid and Lymphoid Malignancies in Patients with Myeloproliferative Neoplasms: Clinical Implications

  2020cites this paper
• University of Southern Denmark Risks of solid and lymphoid malignancies in patients with myeloproliferative neoplasms

  2020cites this paper
• Polycythemia Vera era 1939-1998 from Berkeley to Rotterdam and Change of PVSG into ECP Criteria of Myeloproliferative Disorders ET, PV and PMGM: Proceedings of the First Rotterdam MPD Workshop 1998 and beyond

  2017cites this paper
• Reactor-Produced Therapeutic Radionuclides

  2016cites this paper
• Reactor production of 32P for medical applications: an assessment of 32S(n,p)32P and 31P(n,γ)32P methods

  2014cites this paper
• Ruxolitinib for myelofibrosis

  2013cites this paper
• Hydroxyurea for the treatment of sickle cell disease: Efficacy, barriers, toxicity, and management in children

  2012influential citation
• Ruxolitinib for the treatment of myelofibrosis: its clinical potential

  2012cites this paper
• Ruxolitinib for the treatment of myelofibrosis.

  2011cites this paper
• Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.

  2011cites this paper
• Essential Thrombocythemia (ET)

  2010cites this paper
• Polycythemia Vera (PV)

  2010cites this paper
• New perspectives in managing myeloproliferative disorders: focus on the patient

  2009cites this paper
• Guidelines for the diagnosis and treatment of patients with polycythemia vera, essential thrombocythemia and primary myelofibrosis.

  2009cites this paper
• Anagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologists

  2009cites this paper
• Diagnosis and treatment of polycythemia vera: Brazilian experience from a single institution

  2008cites this paper
• Essential thrombocythaemia treatment options: addressing patient‐specific needs

  2007cites this paper
• The Impact of Clinicopathological Studies on Staging and Survival in Essential Thrombocythemia, Chronic Idiopathic Myelofibrosis, and Polycythemia Rubra Vera

  2006cites this paper
• The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera.

  2006cites this paper
• Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia

  2006cites this paper
• Myeloproliferative Erkrankungen — Polycythaemia vera, idiopathische Myelofibrose, essentielle Thrombozythämie

  2006cites this paper
• Treatment paradigms in the management of myeloproliferative disorders.

  2004cites this paper
• Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival.

  2004cites this paper
• Use and risks of phosphorus-32 in the treatment of polycythaemia vera

  2003cites this paper
• Polycythemia vera: myths, mechanisms, and management.

  2002cites this paper
• Onset of oral extranodal large B-cell non-Hodgkin's lymphoma in a patient with polycythemia vera: a rare presentation.

  2002cites this paper
• Current management in polycythemia vera.

  2001cites this paper
• Clinical syndromes of transformation in clonal hematologic disorders.

  2001cites this paper
• A Polycythemia Vera Updated: Diagnosis, Pathobiology, and Treatment.

  2000cites this paper
• A clinical update in polycythemia vera and essential thrombocythemia.

  2000cites this paper
• Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta‐analysis of three randomized trials

  2000cites this paper
• Introduction: overview of chronic myeloproliferative disorders.

  1999cites this paper
• Treatment of polycythaemia vera and essential thrombocythaemia.

  1998cites this paper
• 4 Treatment of polycythaemia vera and essential thrombocythaemia

  1998cites this paper
• The Management of Polycythaemia Vera.

  1997cites this paper
• . Exposure Data 2. Cancer in Humans 2.1 Pure Β-particle Emitters 2.1.1 Tritium

  year unknowncites this paper